Exploration of the mechanism of luteolin against ischemic stroke based on network pharmacology, molecular docking and experimental verification

References

• Rothwell PM, Algra A, Amarenco P. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet. 2011;377(9778):1681–1692.
   PubMed Web of Science ®Google Scholar
• Hachinski V, Azarpazhooh MR. Stroke is a burdensome but preventable brain disorder. Lancet Neurol. 2016;15(9):892–893.
   PubMed Web of Science ®Google Scholar
• Zheng Y , He R , Wang P , Shi Y , Zhao L , Liang J . Exosomes from LPS-stimulated macrophages induce neuroprotection and functional improvement after ischemic stroke by modulating microglial polarization. Biomater Sci. 2019 Apr 23;7(5):2037-2049. doi: 10.1039/c8bm01449c.
   Google Scholar
• Dong R, Huang R, Wang J, et al. Effects of microglial activation and polarization on brain injury after stroke. Front Neurol. 2021;12:620948.
   PubMed Web of Science ®Google Scholar
• Modig K, Talback M, Ziegler L, et al. Temporal trends in incidence, recurrence and prevalence of stroke in an era of ageing populations, a longitudinal study of the total Swedish population. BMC Geriatr. 2019;19(1):31.
   PubMedGoogle Scholar
• Barthels D, Das H. Current advances in ischemic stroke research and therapies. Biochim Biophys Acta Mol Basis Dis. 2020;1866(4):165260.
   PubMed Web of Science ®Google Scholar
• Bennion DM, Steckelings UM, Sumners C. Neuroprotection via AT2 receptor agonists in ischemic stroke. Clin Sci (Lond). 2018;132(10):1055–1067.
   PubMed Web of Science ®Google Scholar
• Xu H, Qin W, Hu X, Mu S, Zhu J, Lu W, Luo Y. Lentivirus-mediated overexpression of OTULIN ameliorates microglia activation and neuroinflammation by depressing the activation of the NF-κB signaling pathway in cerebral ischemia/reperfusion rats. J Neuroinflammation. 2018 Mar 15;15(1):83. doi: 10.1186/s12974-018-1117-5
   Google Scholar
• Lian L, Zhang Y, Liu L, et al. Neuroinflammation in ischemic stroke: focus on MicroRNA-mediated polarization of Microglia. Front Mol Neurosci. 2020;13:612439.
   PubMed Web of Science ®Google Scholar
• Pan Y, Jiao Q, Wei W, et al. Emerging Role of LncRNAs in ischemic stroke-novel insights into the regulation of Inflammation. J Inflamm Res. 2021;14:4467–4483.
   PubMed Web of Science ®Google Scholar
• Xin WQ, Wei W, Pan Y-L, et al. Modulating poststroke inflammatory mechanisms: novel aspects of mesenchymal stem cells, extracellular vesicles and microglia. World J Stem Cells. 2021;13(8):1030–1048.
   PubMed Web of Science ®Google Scholar
• Liang W, Huang X, Chen W. The effects of Baicalin and Baicalein on Cerebral Ischemia: a review. Aging Dis. 2017;8(6):850–867.
   PubMed Web of Science ®Google Scholar
• Caltagirone C, Cisari C, Schievano C, et al. Co-ultramicronized palmitoylethanolamide/luteolin in the treatment of cerebral ischemia: from rodent to man. Transl Stroke Res. 2016;7(1):54–69.
   PubMed Web of Science ®Google Scholar
• Hung IL, Hung Y-C, Wang L-Y, et al. Chinese herbal products for ischemic stroke. Am J Chin Med. 2015;43(7):1365–1379.
   PubMed Web of Science ®Google Scholar
• Peng W, Lauche R, Ferguson C, et al. Efficacy of Chinese herbal medicine for stroke modifiable risk factors: a systematic review. Chin Med. 2017;12(1):25.
   PubMedGoogle Scholar
• Yuwen Y, Shi -N-N, Han X-J, et al. Appraisal of clinical practice guidelines for ischemic stroke management in Chinese medicine with appraisal of guidelines for research and evaluation instrument: a systematic review. Chin J Integr Med. 2015;21(9):707–715.
   PubMed Web of Science ®Google Scholar
• Zhang B, Saatman KE, Chen L. Therapeutic potential of natural compounds from Chinese medicine in acute and subacute phases of ischemic stroke. Neural Regen Res. 2020;15(3):416–424.
   PubMed Web of Science ®Google Scholar
• Pandurangan AK, Esa NM. Luteolin, a bioflavonoid inhibits colorectal cancer through modulation of multiple signaling pathways: a review. Asian Pac J Cancer Prev. 2014;15(14):5501–5508.
   PubMedGoogle Scholar
• Sawmiller D, Li S, Shahaduzzaman M, Smith AJ, Obregon D, Giunta B, Borlongan CV, Sanberg PR, Tan J. Luteolin reduces Alzheimer's disease pathologies induced by traumatic brain injury. Int J Mol Sci. 2014 Jan 9;15(1):895-904. doi: 10.3390/ijms15010895. PMID: 24413756; PMCID: PMC3907845.
   Google Scholar
• Luo S, Li H, Mo Z, et al. Connectivity map identifies luteolin as a treatment option of ischemic stroke by inhibiting MMP9 and activation of the PI3K/Akt signaling pathway. Exp Mol Med. 2019;51(3):1–11.
   Google Scholar
• Zhao G, Zang SY, Jiang ZH, Chen YY, Ji XH, Lu BF, Wu JH, Qin GW, Guo LH. Postischemic administration of liposome-encapsulated luteolin prevents against ischemia-reperfusion injury in a rat middle cerebral artery occlusion model. J Nutr Biochem. 2011 Oct;22(10):929-36. doi: 10.1016/j.jnutbio.2010.07.014. Epub 2010 Dec 28. PMID: 21190830.
   Google Scholar
• Ashaari Z, Hadjzadeh M-A-R, Hassanzadeh G, et al. The flavone luteolin improves central nervous system disorders by different mechanisms: a review. J Mol Neurosci. 2018;65(4):491–506.
   PubMed Web of Science ®Google Scholar
• Zeng L, Yang K. Exploring the pharmacological mechanism of Yanghe Decoction on HER2-positive breast cancer by a network pharmacology approach. J Ethnopharmacol. 2017;199:68–85.
   PubMed Web of Science ®Google Scholar
• Ru J, Li P, Wang J, Zhou W, Li B, Huang C, Li P, Guo Z, Tao W, Yang Y, Xu X, Li Y, Wang Y, Yang L. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014 Apr 16;6:13. doi: 10.1186/1758-2946-6-13. PMID: 24735618; PMCID: PMC4001360.
   Google Scholar
• Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335.
   Google Scholar
• Wang Y, Zhang S, Li F, Zhou Y, Zhang Y, Wang Z, Zhang R, Zhu J, Ren Y, Tan Y, Qin C, Li Y, Li X, Chen Y, Zhu F. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res. 2020 Jan 8;48(D1):D1031-D1041. doi: 10.1093/nar/gkz981. PMID: 31691823; PMCID: PMC7145558.
   Google Scholar
• UniProt C. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019;47:D506–D515.
   PubMed Web of Science ®Google Scholar
• Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X, Lai L, Pei J, Li H. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017 Jul 3;45(W1):W356-W360. doi: 10.1093/nar/gkx374. PMID: 28472422; PMCID: PMC5793840.
   Google Scholar
• Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecule s. Nucleic Acids Res. 2019;47(W1):W357–W364.
   PubMed Web of Science ®Google Scholar
• Davis AP, Grondin CJ, Johnson RJ, Sciaky D, Wiegers J, Wiegers TC, Mattingly CJ. Comparative Toxicogenomics Database (CTD): update 2021. Nucleic Acids Res. 2021 Jan 8;49(D1):D1138-D1143. doi: 10.1093/nar/gkaa891. PMID: 33068428; PMCID: PMC7779006.
   Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613.
   PubMed Web of Science ®Google Scholar
• Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol. 2011;696:291–303.
   PubMedGoogle Scholar
• Fonseka P, Pathan M, Chitti SV, et al. FunRich enables enrichment analysis of OMICs datasets. J Mol Biol. 2020;433(11):166747.
   PubMed Web of Science ®Google Scholar
• Guan M, Guo L, Ma H, et al. Network pharmacology and molecular docking suggest the mechanism for biological activity of rosmarinic acid. Evid Based Complement Alternat Med. 2021;2021:5190808.
   PubMed Web of Science ®Google Scholar
• Yuan C, Wang M-H, Wang F, et al. Network pharmacology and molecular docking reveal the mechanism of Scopoletin against non-small cell lung cancer. Life Sci. 2021;270:119105.
   PubMed Web of Science ®Google Scholar
• Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
   PubMed Web of Science ®Google Scholar
• Wang M, Liu F, Yao Y, et al. Network pharmacology-based mechanism prediction and pharmacological validation of Xiaoyan Lidan formula on attenuating alpha-naphthylisothiocyanate induced cholestatic hepatic injury in rats. J Ethnopharmacol. 2021;270:113816.
   PubMed Web of Science ®Google Scholar
• Wang G, Wang T, Zhang Y, Li F, Yu B, Kou J. Schizandrin Protects against OGD/R-Induced Neuronal Injury by Suppressing Autophagy: Involvement of the AMPK/mTOR Pathway. Molecules. 2019 Oct 8;24(19):3624. doi: 10.3390/molecules24193624. PMID: 31597329; PMCID: PMC6804185.
   Google Scholar
• Liu X, Zhu X, Chen M, et al. Resveratrol protects PC12 cells against OGD/ R-induced apoptosis via the mitochondrial-mediated signaling pathway. Acta Biochim Biophys Sin (Shanghai). 2016;48(4):342–353.
   PubMed Web of Science ®Google Scholar
• Wang JQ, Dong Y, Li S-J, et al. Knockdown of microRNA-17-5p enhances the neuroprotective effect of Act A/Smads signal loop after ischemic injury. Neurochem Res. 2019;44(8):1807–1817.
   PubMed Web of Science ®Google Scholar
• Liu C, Yin Z, Feng T, et al. An integrated network pharmacology and RNA-Seq approach for exploring the preventive effect of Lonicerae japonicae flos on LPS-induced acute lung injury. J Ethnopharmacol. 2021;264:113364.
   PubMed Web of Science ®Google Scholar
• Yang Z, Wang L, Hu Y, et al. Butorphanol protects PC12 cells against OGD/R-induced inflammation and apoptosis. Mol Med Rep. 2020;22(3):1969–1975.
   PubMed Web of Science ®Google Scholar
• Tao Q, Du J, Li X, et al. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19. Drug Dev Ind Pharm. 2020;46(8):1345–1353.
   PubMed Web of Science ®Google Scholar
• Li X, Lin B, Lin Z, et al. Exploration in the mechanism of fucosterol for the treatment of non-small cell lung cancer based on network pharmacology and molecular docking. Sci Rep. 2021;11(1):4901.
   PubMed Web of Science ®Google Scholar
• Saikia S, Bordoloi M. Molecular docking: challenges, advances and its use in drug discovery perspective. Curr Drug Targets. 2019;20(5):501–521.
   PubMed Web of Science ®Google Scholar
• Lambertsen KL, Finsen B, Clausen BH. Post-stroke inflammation-target or tool for therapy? Acta Neuropathol. 2019;137(5):693–714.
   PubMed Web of Science ®Google Scholar
• Tuttolomondo A, Pecoraro R, Pinto A. Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date. Drug Des Devel Ther. 2014;8:2221–2238.
   PubMed Web of Science ®Google Scholar
• Reibman J, Talbot AT, Hsu Y, et al. Regulation of expression of granulocyte-macrophage colony-stimulating factor in human bronchial epithelial cells: roles of protein kinase C and mitogen-activated protein kinases. J Immunol. 2000;165(3):1618–1625.
   PubMed Web of Science ®Google Scholar
• Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy–from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta. 2005;1754(1–2):253–262.
   PubMed Web of Science ®Google Scholar
• Kim DC, Quang TH, Oh H, et al. Steppogenin isolated from cudrania tricuspidata shows antineuroinflammatory effects via NF-kappaB and MAPK pathways in LPS-Stimulated BV2 and primary rat microglial cells. Molecules. 2017;22(12):2130.
   Web of Science ®Google Scholar
• Wang Z, Wang W, Xu S, et al. The role of MAPK signaling pathway in the Her-2-positive meningiomas. Oncol Rep. 2016;36(2):685–695.
   PubMed Web of Science ®Google Scholar
• Zhao P, Chang R-Y, Liu N, et al. Neuroprotective effect of oxysophocarpine by modulation of MAPK pathway in rat hippocampal neurons subject to oxygen-glucose deprivation and reperfusion. Cell Mol Neurobiol. 2018;38(2):529–540.
   PubMed Web of Science ®Google Scholar
• Qi Z, Qi S, Gui L, et al. Daphnetin protects oxidative stress-induced neuronal apoptosis via regulation of MAPK signaling and HSP70 expression. Oncol Lett. 2016;12(3):1959–1964.
   PubMed Web of Science ®Google Scholar
• Liu SY, Xu P, Luo XL, et al. (7R,8S)-Dehydrodiconiferyl alcohol suppresses lipopolysaccharide-induced inflammatory responses in BV2 microglia by inhibiting MAPK signaling. Neurochem Res. 2016;41(7):1570–1577.
   PubMed Web of Science ®Google Scholar
• Choudhury S, Ghosh S, Gupta P, et al. Inflammation-induced ROS generation causes pancreatic cell death through modulation of Nrf2/NF-kappaB and SAPK/JNK pathway. Free Radic Res. 2015;49(11):1371–1383.
   PubMed Web of Science ®Google Scholar
• Patrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol. 2016;82(4):957–964.
   PubMed Web of Science ®Google Scholar
• You HJ, Han SK, Rhie JW. Randomised controlled clinical trial for autologous fibroblast-hyaluronic acid complex in treating diabetic foot ulcers. J Wound Care. 2014;23(11):521–522, 524, 526–530.
   PubMed Web of Science ®Google Scholar
• Blume PA, Walters J, Payne W, et al. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care. 2008;31(4):631–636.
   PubMed Web of Science ®Google Scholar
• Zhao L, Fang J, Zhou M, et al. Interaction between COX-1 and COX-2 increases susceptibility to ischemic stroke in a Chinese population. BMC Neurol. 2019;19(1):291.
   PubMed Web of Science ®Google Scholar
• Yi X, Lin J, Luo H, et al. Genetic variants of PTGS2, TXA2R and TXAS1 are associated with carotid plaque vulnerability, platelet activation and TXA2 levels in ischemic stroke patients. PLoS One. 2017;12(7):e0180704.
   PubMed Web of Science ®Google Scholar
• Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38(1):97–120.
   PubMed Web of Science ®Google Scholar
• Dong H, Cui B, Hao X. MicroRNA22 alleviates inflammation in ischemic stroke via p38 MAPK pathways. Mol Med Rep. 2019;20(1):735–744.
   PubMed Web of Science ®Google Scholar
• He T, Wang J, Wang XL, et al. Association between the matrix metalloproteinase-9 rs3918242 polymorphism and ischemic stroke susceptibility: a meta-analysis. J Stroke Cerebrovasc Dis. 2017;26(5):1136–1143.
   PubMed Web of Science ®Google Scholar
• Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008;75(2):346–359.
   PubMed Web of Science ®Google Scholar
• Spampinato SF, Merlo S, Sano Y, et al. Astrocytes contribute to Abeta-induced blood-brain barrier damage through activation of endothelial MMP9. J Neurochem. 2017;142(3):464–477.
   PubMed Web of Science ®Google Scholar
• Turner RJ, Sharp FR. Implications of MMP9 for blood brain barrier disruption and hemorrhagic transformation following ischemic stroke. Front Cell Neurosci. 2016;10:56.
   PubMed Web of Science ®Google Scholar
• Rosell A, Ortega-Aznar A, Alvarez-Sabin J, et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. 2006;37(6):1399–1406.
   PubMed Web of Science ®Google Scholar
• Zhong C, Yang J, Xu T, et al. Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke. Neurology. 2017;89(8):805–812.
   PubMed Web of Science ®Google Scholar
• Yang Y, Estrada EY, Thompson JF, et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab. 2007;27(4):697–709.
   PubMed Web of Science ®Google Scholar
• Chen AQ, Fang Z, Chen X-L, et al. Microglia-derived TNF-alpha mediates endothelial necroptosis aggravating blood brain-barrier disruption after ischemic stroke. Cell Death Dis. 2019;10(7):487.
   PubMedGoogle Scholar
• Stellwagen D, Beattie EC, Seo JY, et al. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci. 2005;25(12):3219–3228.
   PubMed Web of Science ®Google Scholar
• Siasos G, Tousoulis D, Kioufis S, Oikonomou E, Siasou Z, Limperi M, Papavassiliou AG, Stefanadis C. Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases. Curr Top Med Chem. 2012;12(10):1132-48. doi: 10.2174/1568026611208011132. PMID: 22519444.
   Google Scholar
• Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, et al. Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats. J Neurochem. 2007;100(4):1108–1120.
   PubMed Web of Science ®Google Scholar
• Yang C, Yang Y, DeMars KM, et al. Genetic deletion or pharmacological inhibition of cyclooxygenase-2 reduces blood-brain barrier damage in experimental ischemic stroke. Front Neurol. 2020;11:887.
   PubMed Web of Science ®Google Scholar
• Zheng J, Dai Q, Han K, Hong W, Jia D, Mo Y, Lv Y, Tang H, Fu H, Geng W. JNK-IN-8, a c-Jun N-terminal kinase inhibitor, improves functional recovery through suppressing neuroinflammation in ischemic stroke. J Cell Physiol. 2020 Mar;235(3):2792-2799. doi: 10.1002/jcp.29183. Epub 2019 Sep 20. PMID: 31541462; PMCID: PMC6916328.
   Google Scholar
• Qin S, Yang C, Huang W, Du S, Mai H, Xiao J, Lü T. Sulforaphane attenuates microglia-mediated neuronal necroptosis through down-regulation of MAPK/NF-κB signaling pathways in LPS-activated BV-2 microglia. Pharmacol Res. 2018 Jul;133:218-235. doi: 10.1016/j.phrs.2018.01.014. Epub 2018 Jan 31. PMID: 29391237.
   Google Scholar
• Yamazaki Y, Arita K, Harada S, et al. Activation of c-Jun N-terminal kinase and p38 after cerebral ischemia upregulates cerebral sodium-glucose transporter type 1. J Pharmacol Sci. 2018;138(4):240–246.
   PubMed Web of Science ®Google Scholar
• Wen J, Watanabe K, Ma M, Yamaguchi K, Tachikawa H, Kodama M, Aizawa Y. Edaravone inhibits JNK-c-Jun pathway and restores anti-oxidative defense after ischemia-reperfusion injury in aged rats. Biol Pharm Bull. 2006 Apr;29(4):713-8. doi: 10.1248/bpb.29.713. PMID: 16595905.
   Google Scholar
• Yu L, Yang B, Wang J, et al. Time course change of COX2-PGI2/TXA2 following global cerebral ischemia reperfusion injury in rat hippocampus. Behav Brain Funct. 2014;10(1):42.
   PubMedGoogle Scholar
• Li H, Zhou S, Wu L, Liu K, Zhang Y, Ma G, Wang L. The role of p38MAPK signal pathway in the neuroprotective mechanism of limb postconditioning against rat cerebral ischemia/reperfusion injury. J Neurol Sci. 2015 Oct 15;357(1-2):270-5. doi: 10.1016/j.jns.2015.08.004. Epub 2015 Aug 5. PMID: 26282496.
   Google Scholar
• Sasaki T, Kitagawa K, Yamagata K, et al. Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase-2-deficient mice. J Cereb Blood Flow Metab. 2004;24(1):107–113.
   PubMed Web of Science ®Google Scholar
• Dore S, Otsuka T, Mito T, et al. Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol. 2003;54(2):155–162.
   PubMed Web of Science ®Google Scholar
• Iadecola C, Niwa K, Nogawa S, et al. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A. 2001;98(3):1294–1299.
   PubMed Web of Science ®Google Scholar